Compile Data Set for Download or QSAR
maximum 50k data
Found 50 Enz. Inhib. hit(s) with all data for entry = 10175
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Clavius Pharmaceuticals

US Patent
LigandPNGBDBM518497(US11124509, Compound 68)
Affinity DataIC50:  1.20nMAssay Description:Exemplified compounds were screened in 1% DMSO (final concentration) by 3-fold serial dilutions from 10,000 nM to 0.316 nM to produce an IC50 or at s...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Clavius Pharmaceuticals

US Patent
LigandPNGBDBM518501(US11124509, Compound 69)
Affinity DataIC50:  3nMAssay Description:Exemplified compounds were screened in 1% DMSO (final concentration) by 3-fold serial dilutions from 10,000 nM to 0.316 nM to produce an IC50 or at s...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Clavius Pharmaceuticals

US Patent
LigandPNGBDBM518482(US11124509, Compound 55)
Affinity DataIC50:  4.71nMAssay Description:Exemplified compounds were screened in 1% DMSO (final concentration) by 3-fold serial dilutions from 10,000 nM to 0.316 nM to produce an IC50 or at s...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Clavius Pharmaceuticals

US Patent
LigandPNGBDBM518474(US11124509, Compound 46)
Affinity DataIC50:  5.60nMAssay Description:Exemplified compounds were screened in 1% DMSO (final concentration) by 3-fold serial dilutions from 10,000 nM to 0.316 nM to produce an IC50 or at s...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Clavius Pharmaceuticals

US Patent
LigandPNGBDBM518465(US11124509, Compound 37)
Affinity DataIC50:  5.60nMAssay Description:Exemplified compounds were screened in 1% DMSO (final concentration) by 3-fold serial dilutions from 10,000 nM to 0.316 nM to produce an IC50 or at s...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Clavius Pharmaceuticals

US Patent
LigandPNGBDBM518475(US11124509, Compound 47)
Affinity DataIC50:  6.60nMAssay Description:Exemplified compounds were screened in 1% DMSO (final concentration) by 3-fold serial dilutions from 10,000 nM to 0.316 nM to produce an IC50 or at s...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Clavius Pharmaceuticals

US Patent
LigandPNGBDBM518472(US11124509, Compound 44)
Affinity DataIC50:  6.66nMAssay Description:Exemplified compounds were screened in 1% DMSO (final concentration) by 3-fold serial dilutions from 10,000 nM to 0.316 nM to produce an IC50 or at s...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Clavius Pharmaceuticals

US Patent
LigandPNGBDBM518488(US11124509, Compound 61)
Affinity DataIC50:  7.55nMAssay Description:Exemplified compounds were screened in 1% DMSO (final concentration) by 3-fold serial dilutions from 10,000 nM to 0.316 nM to produce an IC50 or at s...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Clavius Pharmaceuticals

US Patent
LigandPNGBDBM518481(US11124509, Compound 54)
Affinity DataIC50:  31.2nMAssay Description:Exemplified compounds were screened in 1% DMSO (final concentration) by 3-fold serial dilutions from 10,000 nM to 0.316 nM to produce an IC50 or at s...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Clavius Pharmaceuticals

US Patent
LigandPNGBDBM518469(US11124509, Compound 41)
Affinity DataIC50:  33nMAssay Description:Exemplified compounds were screened in 1% DMSO (final concentration) by 3-fold serial dilutions from 10,000 nM to 0.316 nM to produce an IC50 or at s...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Clavius Pharmaceuticals

US Patent
LigandPNGBDBM518483(US11124509, Compound 56)
Affinity DataIC50:  43.6nMAssay Description:Exemplified compounds were screened in 1% DMSO (final concentration) by 3-fold serial dilutions from 10,000 nM to 0.316 nM to produce an IC50 or at s...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Clavius Pharmaceuticals

US Patent
LigandPNGBDBM518491(US11124509, Compound 64)
Affinity DataIC50:  44.6nMAssay Description:Exemplified compounds were screened in 1% DMSO (final concentration) by 3-fold serial dilutions from 10,000 nM to 0.316 nM to produce an IC50 or at s...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Clavius Pharmaceuticals

US Patent
LigandPNGBDBM518489(US11124509, Compound 62)
Affinity DataIC50:  45.8nMAssay Description:Exemplified compounds were screened in 1% DMSO (final concentration) by 3-fold serial dilutions from 10,000 nM to 0.316 nM to produce an IC50 or at s...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Clavius Pharmaceuticals

US Patent
LigandPNGBDBM518492(US11124509, Compound 65)
Affinity DataIC50:  46.2nMAssay Description:Exemplified compounds were screened in 1% DMSO (final concentration) by 3-fold serial dilutions from 10,000 nM to 0.316 nM to produce an IC50 or at s...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Clavius Pharmaceuticals

US Patent
LigandPNGBDBM518467(US11124509, Compound 39)
Affinity DataIC50:  46.4nMAssay Description:Exemplified compounds were screened in 1% DMSO (final concentration) by 3-fold serial dilutions from 10,000 nM to 0.316 nM to produce an IC50 or at s...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Clavius Pharmaceuticals

US Patent
LigandPNGBDBM518462(US11124509, Compound 34)
Affinity DataIC50:  49nMAssay Description:Exemplified compounds were screened in 1% DMSO (final concentration) by 3-fold serial dilutions from 10,000 nM to 0.316 nM to produce an IC50 or at s...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Clavius Pharmaceuticals

US Patent
LigandPNGBDBM518496(US11124509, Compound 67)
Affinity DataIC50:  50nMAssay Description:Exemplified compounds were screened in 1% DMSO (final concentration) by 3-fold serial dilutions from 10,000 nM to 0.316 nM to produce an IC50 or at s...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Clavius Pharmaceuticals

US Patent
LigandPNGBDBM518487(US11124509, Compound 60)
Affinity DataIC50:  71.7nMAssay Description:Exemplified compounds were screened in 1% DMSO (final concentration) by 3-fold serial dilutions from 10,000 nM to 0.316 nM to produce an IC50 or at s...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Clavius Pharmaceuticals

US Patent
LigandPNGBDBM518485(US11124509, Compound 58)
Affinity DataIC50:  78nMAssay Description:Exemplified compounds were screened in 1% DMSO (final concentration) by 3-fold serial dilutions from 10,000 nM to 0.316 nM to produce an IC50 or at s...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Clavius Pharmaceuticals

US Patent
LigandPNGBDBM518473(US11124509, Compound 45)
Affinity DataIC50: <100nMAssay Description:Exemplified compounds were screened in 1% DMSO (final concentration) by 3-fold serial dilutions from 10,000 nM to 0.316 nM to produce an IC50 or at s...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Clavius Pharmaceuticals

US Patent
LigandPNGBDBM518468(US11124509, Compound 40)
Affinity DataIC50: <100nMAssay Description:Exemplified compounds were screened in 1% DMSO (final concentration) by 3-fold serial dilutions from 10,000 nM to 0.316 nM to produce an IC50 or at s...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Clavius Pharmaceuticals

US Patent
LigandPNGBDBM518466(US11124509, Compound 38)
Affinity DataIC50: <100nMAssay Description:Exemplified compounds were screened in 1% DMSO (final concentration) by 3-fold serial dilutions from 10,000 nM to 0.316 nM to produce an IC50 or at s...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Clavius Pharmaceuticals

US Patent
LigandPNGBDBM518459(US11124509, Compound 29)
Affinity DataIC50: <100nMAssay Description:Exemplified compounds were screened in 1% DMSO (final concentration) by 3-fold serial dilutions from 10,000 nM to 0.316 nM to produce an IC50 or at s...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Clavius Pharmaceuticals

US Patent
LigandPNGBDBM518458(US11124509, Compound 28)
Affinity DataIC50: <100nMAssay Description:Exemplified compounds were screened in 1% DMSO (final concentration) by 3-fold serial dilutions from 10,000 nM to 0.316 nM to produce an IC50 or at s...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Clavius Pharmaceuticals

US Patent
LigandPNGBDBM518457(US11124509, Compound 27)
Affinity DataIC50: <100nMAssay Description:Exemplified compounds were screened in 1% DMSO (final concentration) by 3-fold serial dilutions from 10,000 nM to 0.316 nM to produce an IC50 or at s...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Clavius Pharmaceuticals

US Patent
LigandPNGBDBM518456(US11124509, Compound 26)
Affinity DataIC50: <100nMAssay Description:Exemplified compounds were screened in 1% DMSO (final concentration) by 3-fold serial dilutions from 10,000 nM to 0.316 nM to produce an IC50 or at s...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Clavius Pharmaceuticals

US Patent
LigandPNGBDBM518454(US11124509, Compound 22)
Affinity DataIC50: <100nMAssay Description:Exemplified compounds were screened in 1% DMSO (final concentration) by 3-fold serial dilutions from 10,000 nM to 0.316 nM to produce an IC50 or at s...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Clavius Pharmaceuticals

US Patent
LigandPNGBDBM518453(US11124509, Compound 20)
Affinity DataIC50: <100nMAssay Description:Exemplified compounds were screened in 1% DMSO (final concentration) by 3-fold serial dilutions from 10,000 nM to 0.316 nM to produce an IC50 or at s...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Clavius Pharmaceuticals

US Patent
LigandPNGBDBM518471(US11124509, Compound 43)
Affinity DataIC50: <100nMAssay Description:Exemplified compounds were screened in 1% DMSO (final concentration) by 3-fold serial dilutions from 10,000 nM to 0.316 nM to produce an IC50 or at s...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Clavius Pharmaceuticals

US Patent
LigandPNGBDBM518476(US11124509, Compound 48)
Affinity DataIC50: <100nMAssay Description:Exemplified compounds were screened in 1% DMSO (final concentration) by 3-fold serial dilutions from 10,000 nM to 0.316 nM to produce an IC50 or at s...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Clavius Pharmaceuticals

US Patent
LigandPNGBDBM518463(US11124509, Compound 36)
Affinity DataIC50:  103nMAssay Description:Exemplified compounds were screened in 1% DMSO (final concentration) by 3-fold serial dilutions from 10,000 nM to 0.316 nM to produce an IC50 or at s...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Clavius Pharmaceuticals

US Patent
LigandPNGBDBM518484(US11124509, Compound 57)
Affinity DataIC50:  128nMAssay Description:Exemplified compounds were screened in 1% DMSO (final concentration) by 3-fold serial dilutions from 10,000 nM to 0.316 nM to produce an IC50 or at s...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Clavius Pharmaceuticals

US Patent
LigandPNGBDBM518478(US11124509, Compound 50)
Affinity DataIC50:  138nMAssay Description:Exemplified compounds were screened in 1% DMSO (final concentration) by 3-fold serial dilutions from 10,000 nM to 0.316 nM to produce an IC50 or at s...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Clavius Pharmaceuticals

US Patent
LigandPNGBDBM518461(US11124509, Compound 33)
Affinity DataIC50: <200nMAssay Description:Exemplified compounds were screened in 1% DMSO (final concentration) by 3-fold serial dilutions from 10,000 nM to 0.316 nM to produce an IC50 or at s...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Clavius Pharmaceuticals

US Patent
LigandPNGBDBM518455(US11124509, Compound 24)
Affinity DataIC50: <200nMAssay Description:Exemplified compounds were screened in 1% DMSO (final concentration) by 3-fold serial dilutions from 10,000 nM to 0.316 nM to produce an IC50 or at s...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Clavius Pharmaceuticals

US Patent
LigandPNGBDBM518479(US11124509, Compound 51)
Affinity DataIC50:  260nMAssay Description:Exemplified compounds were screened in 1% DMSO (final concentration) by 3-fold serial dilutions from 10,000 nM to 0.316 nM to produce an IC50 or at s...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Clavius Pharmaceuticals

US Patent
LigandPNGBDBM518450(US11124509, Compound 10)
Affinity DataIC50:  264nMAssay Description:Exemplified compounds were screened in 1% DMSO (final concentration) by 3-fold serial dilutions from 10,000 nM to 0.316 nM to produce an IC50 or at s...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Clavius Pharmaceuticals

US Patent
LigandPNGBDBM518495(US11124509, Compound 66)
Affinity DataIC50:  285nMAssay Description:Exemplified compounds were screened in 1% DMSO (final concentration) by 3-fold serial dilutions from 10,000 nM to 0.316 nM to produce an IC50 or at s...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Clavius Pharmaceuticals

US Patent
LigandPNGBDBM518448(US11124509, Compound 6)
Affinity DataIC50:  354nMAssay Description:Exemplified compounds were screened in 1% DMSO (final concentration) by 3-fold serial dilutions from 10,000 nM to 0.316 nM to produce an IC50 or at s...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Clavius Pharmaceuticals

US Patent
LigandPNGBDBM518490(US11124509, Compound 63)
Affinity DataIC50:  399nMAssay Description:Exemplified compounds were screened in 1% DMSO (final concentration) by 3-fold serial dilutions from 10,000 nM to 0.316 nM to produce an IC50 or at s...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Clavius Pharmaceuticals

US Patent
LigandPNGBDBM518449(US11124509, Compound 8)
Affinity DataIC50:  811nMAssay Description:Exemplified compounds were screened in 1% DMSO (final concentration) by 3-fold serial dilutions from 10,000 nM to 0.316 nM to produce an IC50 or at s...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Clavius Pharmaceuticals

US Patent
LigandPNGBDBM518486(US11124509, Compound 59)
Affinity DataIC50:  889nMAssay Description:Exemplified compounds were screened in 1% DMSO (final concentration) by 3-fold serial dilutions from 10,000 nM to 0.316 nM to produce an IC50 or at s...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Clavius Pharmaceuticals

US Patent
LigandPNGBDBM518452(US11124509, Compound 17)
Affinity DataIC50: <1.00E+3nMAssay Description:Exemplified compounds were screened in 1% DMSO (final concentration) by 3-fold serial dilutions from 10,000 nM to 0.316 nM to produce an IC50 or at s...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Clavius Pharmaceuticals

US Patent
LigandPNGBDBM518470(US11124509, Compound 42)
Affinity DataIC50: <1.00E+3nMAssay Description:Exemplified compounds were screened in 1% DMSO (final concentration) by 3-fold serial dilutions from 10,000 nM to 0.316 nM to produce an IC50 or at s...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Clavius Pharmaceuticals

US Patent
LigandPNGBDBM518460(US11124509, Compound 31)
Affinity DataIC50: <1.00E+3nMAssay Description:Exemplified compounds were screened in 1% DMSO (final concentration) by 3-fold serial dilutions from 10,000 nM to 0.316 nM to produce an IC50 or at s...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Clavius Pharmaceuticals

US Patent
LigandPNGBDBM518480(US11124509, Compound 53)
Affinity DataIC50: <1.00E+3nMAssay Description:Exemplified compounds were screened in 1% DMSO (final concentration) by 3-fold serial dilutions from 10,000 nM to 0.316 nM to produce an IC50 or at s...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Clavius Pharmaceuticals

US Patent
LigandPNGBDBM518477(US11124509, Compound 49)
Affinity DataIC50: <1.00E+3nMAssay Description:Exemplified compounds were screened in 1% DMSO (final concentration) by 3-fold serial dilutions from 10,000 nM to 0.316 nM to produce an IC50 or at s...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Clavius Pharmaceuticals

US Patent
LigandPNGBDBM518451(US11124509, Compound 16)
Affinity DataIC50: <1.00E+3nMAssay Description:Exemplified compounds were screened in 1% DMSO (final concentration) by 3-fold serial dilutions from 10,000 nM to 0.316 nM to produce an IC50 or at s...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Clavius Pharmaceuticals

US Patent
LigandPNGBDBM518447(US11124509, Compound 4)
Affinity DataIC50:  1.37E+3nMAssay Description:Exemplified compounds were screened in 1% DMSO (final concentration) by 3-fold serial dilutions from 10,000 nM to 0.316 nM to produce an IC50 or at s...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
Clavius Pharmaceuticals

US Patent
LigandPNGBDBM518446(US11124509, Compound 2)
Affinity DataIC50:  1.37E+3nMAssay Description:Exemplified compounds were screened in 1% DMSO (final concentration) by 3-fold serial dilutions from 10,000 nM to 0.316 nM to produce an IC50 or at s...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent